SCHEMBL3012093

SCHEMBL3012093

CC1(C)N=C(c2ccc(F)cc2)c2c(F)cc(NS(C)(=O)=O)cc2O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 5/20 0.43
KIT P10721 3/20 0.38
MAP2K4 P45985 1/20 0.37
BRD4 O60885 3/20 0.36
PTGS2 P35354 2/20 0.36
MEN1 O00255 2/20 0.36
LMNA P02545 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
USP2 O75604 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
KIF11 P52732 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019474 0.90 NR3C2 (0.42) NR3C2KITMAP2K4BRD4PTGS2
SCHEMBL12081689 0.89 KIF11 (0.47) NR3C2PTGS2KIF11
SCHEMBL3030497 0.89 NR3C2 (0.41) NR3C2KITMAP2K4BRD4PTGS2
SCHEMBL12081701 0.85 NR3C2 (0.38) NR3C2KITMAP2K4BRD4
SCHEMBL3025036 0.83 NR3C2 (0.48) NR3C2KITMAP2K4BRD4PTGS2
SCHEMBL12081751 0.78 NR3C2 (0.43) NR3C2KITMAP2K4BRD4PTGS2
SCHEMBL3030401 0.78 KIT (0.38) NR3C2KITBRD4HPGDMAPK1
SCHEMBL3029492 0.77 DGAT1 (0.33)
SCHEMBL3026325 0.75 NR3C2 (0.37) NR3C2KITMAP2K4PTGS2MEN1
SCHEMBL12081720 0.75 KIT (0.45) NR3C2KITBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2179994-B1 FUSED BICYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-26 EP disclosed
US-8410166-B2 Fused bicyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-04-02 US disclosed
US-20130029979-A1 FUSED BICYCLIC COMPOUND TAKAHASHI YOICHI (JP) 2013-01-31 US disclosed
US-8258131-B2 Fused bicyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-09-04 US disclosed
US-20100204218-A1 FUSED BICYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-08-12 US disclosed
EP-2179994-A1 FUSED BICYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029979-A1 FUSED BICYCLIC COMPOUND NR3C2, NR3C1, MC2R NR3C2 1/4885KIT 988/4885MAP2K4 391/4885
US-20100204218-A1 FUSED BICYCLIC COMPOUND NR3C2, NR3C1, MC2R NR3C2 1/4885KIT 859/4885MAP2K4 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.